STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-18)	GEFURULIMAB
PRONUNCIATION	jef" ue roo' li mab
THERAPEUTIC CLAIM	Treatment of diseases caused by complement activation

CHEMICAL NAME

Immunoglobulin, bispecific, anti-(human serum albumin) (human-Lama glama monoclonal ALXN1720 single-domain VHH fragment) fusion protein with peptide linker (synthetic 15 amino-acid) fusion protein with anti-(human complement C5) (human-Lama glama monoclonal ALXN1720 single-domain VHH fragment) (Source: CAS)

STRUCTURAL FORMULA

Sequence

```
EVQLVESGGG  LVKPGGSLRL  SCAASGRPVS  NYAAAWFRQA  PGKEREFVSA    50
INWQKTATYA  DSVKGRFTIS  RDNAKNSLYL  QMNSLRAEDT  AVYYCAAVFR   100
VVAPKTQYDY  DYWGQGTLVT  VSSGGGGAGG  GGAGGGGSEV  QLVESGGGLV   150
QPGGSLRLSC  AASGRAHSDY  AMAWFRQAPG  QEREFVAGIG  WSGGDTLYAD   200
SVRGRFTNSR  DNSKNTLYLQ  MNSLRAEDTA  VYYCAARQGQ  YIYSSMRSDS   250
YDYWGQGTLV  TVSS                                            264
```

Disulfide bridges

22-95 160-234

Glycosylation sites (N)

None

MOLECULAR FORMULA	$C_{1230}H_{1878}N_{356}O_{391}S_{8}$
MOLECULAR WEIGHT	28.16 kDa
TRADEMARK	None as yet
SPONSOR	Alexion Pharmaceuticals, Inc.
CODE DESIGNATIONS	ALXN1720
CAS REGISTRY NUMBER	2456407-94-4
UNII	6PWU78BV6C
WHO NUMBER	11982

gbk